Top Story
SCOTUS State Exchange Decision: What Now for the Rx Industry?
For the second time in three years, the Supreme Court of the United States (SCOTUS) has weighed in on key aspects of the 2010 Obamacare law. This time, the Court has determined that uninsured citizens can now obtain subsidized care, regardless of whether or not a state has set up a State Exchange. Tom Norton reports
...Read more

Value as a decision driver in cancer care: are we there yet?
Read what the experts said at ASCO 2015.

Report
Pharma’s Trillion-Dollar Sales Trophy: Will Payers Pony Up?
A combination of factors – strong science, internal asset management efficiencies, risk tolerant regulators and willing patients – are pushing the biopharma business toward a fresh landmark: $1 trillion in global sales by 2020. That’s the finding from market analytics firm EvaluatePharma’s “World Preview 2015 — Outlook to 2020”. William Looney looks at the report’s predictions
...Read more

Pharma 50
Pharm Exec’s Top 50 Pharma Companies
Our annual Pharma 50 listing is clear proof that once-small and midsize biopharma companies are moving up to join the top ranks of big Pharma. Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others
...Read more

Marketing
Four Launch Mistakes — and How to Avoid Them
In the white heat of a major brand launch, pharma companies can become consumed by the day to day challenges and make mistakes. But some of the worst mistakes can be avoided with a little foresight, writes Ken Begasse.
...Read more

Regulatory
FDA Safety and Innovation Act: Too Many Breakthroughs?
When the breakthrough program was established as part of the FDA Safety and Innovation Act, advocates envisioned about 2–3 designations a year. As of the end of May, the agency had received 308 requests for breakthrough status and had granted the designation for 90. FDA now wants to better educate industry on what really qualifies for breakthrough status, writes Jill Wechsler
...Read more

//OncoMed Pharmaceuticals (Redwoord City, CA) appointed Rick Winningham to its Board of Directors. //Aegerion Pharmaceuticals (Cambridge, MA) appointed Gregory D. Perry as Chief Financial Officer, effective July 6, 2015. Mr. Perry replaces David Aubuchon, interim CFO, who will continue in his role as Chief Accounting Officer. //United Therapeutics Corporation (Silver Springs, MD) appointed Dean Judy D. Olian, Ph.D., to its Board of Directors as an independent director. //TESARO (Waltham, MA) appointed Jeffrey H. Hanke, Ph.D., to the newly created role of Executive Vice President, Research and Development, and Chief Scientific Officer. //